Kynam Capital Management, LP
13F Reported Value
ⓘ$1.6B
incl. option notional
Equity Holdings
ⓘ$1.6B
Option Notional
ⓘ$45.6M
$21.8M puts / $23.8M calls
Holdings
39
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Kynam Capital Management, LP disclosed 39 positions worth $1.6B in its Form 13F-HR for Q1 2026 — $1.6B in common stock plus $45.6M of put/call option positions (reported at underlying notional value, not premium at risk), led by $SNDX (Syndax Pharmaceuticals Inc) at 11.9% of the equity portfolio, followed by $CLDX and $PCVX. During the quarter the fund opened 7 new positions and exited 5 — including a new stake in $URGN and a full exit from $TYRA. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Kynam Capital Management, LP’s Form 13F-HR filing with the SEC under CIK 1907884.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 30.0#2,378
Quality
$188.1M8,050,959 sh - 13.2#2,770
Quality
$185.3M5,840,567 sh - —
Quality
$169.8M2,922,335 sh - —
Quality
$155.4M4,037,331 sh - —
Quality
$136.7M3,398,224 sh - 12.1
Quality
$87.7M3,682,185 sh - 19.1
Quality
$70.6M15,013,093 sh - 37.2
Quality
$54.1M5,680,795 sh - 39.2
Quality
$46.6M1,569,018 sh - 30.5
Quality
$45.8M2,341,652 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Syndax Pharmaceuticals Inc$SNDX | 30.0#2,378 | $188.1M | 8,050,959 |
 Celldex Therapeutics, Inc.$CLDX | 13.2#2,770 | $185.3M | 5,840,567 |
 Vaxcyte, Inc.$PCVX | — | $169.8M | 2,922,335 |
 Cogent Biosciences, Inc.$COGT | — | $155.4M | 4,037,331 |
 Vera Therapeutics, Inc.$VERA | — | $136.7M | 3,398,224 |
 Beam Therapeutics Inc.$BEAM | 12.1 | $87.7M | 3,682,185 |
 CytomX Therapeutics, Inc.$CTMX | 19.1 | $70.6M | 15,013,093 |
 BIOCRYST PHARMACEUTICALS INC$BCRX | 37.2 | $54.1M | 5,680,795 |
 Travere Therapeutics, Inc.$TVTX | 39.2 | $46.6M | 1,569,018 |
 Viridian Therapeutics, Inc.\DE$VRDN | 30.5 | $45.8M | 2,341,652 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Kynam Capital Management, LP's 39 positions.
Showing top 10 of 39 holdings.
Sector Allocation
Healthcare
$1.6B
Full Holdings — Kynam Capital Management, LP (Q1 2026)
All 39 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $SNDX | Syndax Pharmaceuticals Inc | $188.1M | 11.9% | +0% | 30 |
| 2 | $CLDX | Celldex Therapeutics, Inc. | $185.3M | 11.8% | -2% | 13.2 |
| 3 | $PCVX | Vaxcyte, Inc. | $169.8M | 10.8% | +0% | — |
| 4 | $COGT | Cogent Biosciences, Inc. | $155.4M | 9.9% | -35% | — |
| 5 | $VERA | Vera Therapeutics, Inc. | $136.7M | 8.7% | -1% | — |
| 6 | $BEAM | Beam Therapeutics Inc. | $87.7M | 5.6% | +51% | 12.1 |
| 7 | $CTMX | CytomX Therapeutics, Inc. | $70.6M | 4.5% | +67% | 19.1 |
| 8 | $BCRX | BIOCRYST PHARMACEUTICALS INC | $54.1M | 3.4% | -39% | 37.2 |
| 9 | $TVTX | Travere Therapeutics, Inc. | $46.6M | 3.0% | +203% | 39.2 |
| 10 | $VRDN | Viridian Therapeutics, Inc.\DE | $45.8M | 2.9% | +59% | 30.5 |
| 11 |  $CGEM | Cullinan Therapeutics, Inc. | $44.3M | 2.8% | +0% | — |
| 12 |  $URGN | UroGen Pharma Ltd. | $40.4M | 2.6% | NEW | — |
| 13 |  $KALV | KalVista Pharmaceuticals, Inc. | $36.7M | 2.3% | +1% | 25.9 |
| 14 |  $APLS | Apellis Pharmaceuticals, Inc. | $33.2M | 2.1% | -9% | 63.9 |
| 15 |  $LEGN | Legend Biotech Corp | $28.5M | 1.8% | NEW | 44.2 |
| 16 |  $MBX | MBX Biosciences, Inc. | $27.9M | 1.8% | +0% | — |
| 17 |  $IMCR | Immunocore Holdings plc | $26.7M | 1.7% | +3% | — |
| 18 | $TVTXCALL | Travere Therapeutics, Inc. | $23.8M | — | NEW | 39.2 |
| 19 |  $STRO | SUTRO BIOPHARMA, INC. | $21.7M | 1.4% | +82% | 30.1 |
| 20 |  $RVMDPUT | Revolution Medicines, Inc. | $20.2M | — | NEW | — |
| 21 |  $BNR | Burning Rock Biotech Ltd | $19.8M | 1.3% | +23% | — |
| 22 |  $SLNO | SOLENO THERAPEUTICS INC | $18.7M | 1.2% | NEW | 46.3 |
| 23 |  $NRIX | Nurix Therapeutics, Inc. | $18.5M | 1.2% | -39% | 13.2 |
| 24 |  $PHVS | Pharvaris N.V. | $18.1M | 1.1% | +0% | — |
| 25 |  $EVMN | Evommune, Inc. | $14.4M | 0.9% | +237% | — |
| 26 |  $RLAY | Relay Therapeutics, Inc. | $14.2M | 0.9% | +0% | 12.7 |
| 27 |  $GERN | GERON CORP | $10.2M | 0.7% | +98% | — |
| 28 |  $ENGN | enGene Therapeutics Inc. | $9.2M | 0.6% | -9% | — |
| 29 |  $DSGN | Design Therapeutics, Inc. | $8.3M | 0.5% | +0% | — |
| 30 |  $WVE | Wave Life Sciences Ltd. | $7.0M | 0.4% | -56% | — |
| 31 |  $CLYM | Climb Bio, Inc. | $6.9M | 0.4% | -2% | — |
| 32 |  $AMRN | AMARIN CORP PLC\UK | $6.8M | 0.4% | +21% | 22.6 |
| 33 |  $BHVN | Biohaven Ltd. | $5.9M | 0.4% | +0% | — |
| 34 |  $PRLD | Prelude Therapeutics Inc | $5.4M | 0.3% | +102% | 27 |
| 35 |  $CRBU | Caribou Biosciences, Inc. | $4.8M | 0.3% | +0% | 6.1 |
| 36 |  $ALEC | Alector, Inc. | $4.3M | 0.3% | +0% | 8.9 |
| 37 |  $PRQR | ProQR Therapeutics N.V. | $2.5M | 0.2% | +0% | — |
| 38 | $TVTXPUT | Travere Therapeutics, Inc. | $1.6M | — | NEW | 39.2 |
| 39 |  $CADL | Candel Therapeutics, Inc. | $980,000 | 0.1% | NEW | — |
New Positions (7)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Kynam Capital Management, LP including:
Track Kynam Capital Management, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Kynam Capital Management, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Kynam Capital Management, LP
13F Pro is an AI hedge fund tracker and stock research platform. For Kynam Capital Management, LP (SEC CIK: 1907884), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Kynam Capital Management, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.